These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2347056)

  • 1. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.
    Bellmunt J; Morales S; Navarro M; Solé LA
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S81-4. PubMed ID: 2347056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
    Rodriguez MA; Cabanillas FC; Hagemeister FB; McLaughlin P; Romaguera JE; Swan F; Velasquez W
    Ann Oncol; 1995 Jul; 6(6):609-11. PubMed ID: 8573542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer.
    Perez JE; Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Lacava JA; Rodriguez R; Cuevas MA
    J Clin Oncol; 1993 Mar; 11(3):461-6. PubMed ID: 8445421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide combination chemotherapy in advanced breast cancer.
    Schmid H; Kaufmann M; Grischke EM; Bastert G
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S71-3. PubMed ID: 2347055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753.
    Case DC; Santarelli MT; Carey RW; Anderson J; Gottlieb A
    Med Pediatr Oncol; 1992; 20(4):325-9. PubMed ID: 1608355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
    Kosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Polyzos A; Mylonakis N; Karabelis A
    Invest New Drugs; 2007 Oct; 25(5):463-70. PubMed ID: 17370037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.
    Manegold C; Worst P; Bickel J; Schmid H; Drings P; Kaufmann M
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S87-90. PubMed ID: 2112056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
    Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
    Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
    Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
    Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
    Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
    Gurney H; Harnett P; Stuart-Harris R; Kefford R
    Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study.
    Llombart-Cussac A; Pivot X; Rhor-Alvarado A; Le Cesne A; Le Chevalier T; Tursz T; Spielmann M
    Oncology; 1998; 55(5):384-90. PubMed ID: 9732214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas.
    Lorusso V; Paradiso A; Guida M; Berardi F; De Lena M
    Am J Clin Oncol; 1991 Dec; 14(6):492-5. PubMed ID: 1957837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma].
    Huang HQ; Zhou ZM; Li YH; Jiang WQ; He YJ; Teng XY; Guan ZZ
    Ai Zheng; 2002 Apr; 21(4):409-11. PubMed ID: 12452022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
    Sanchiz F; Milla A
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Blumenschein GR; Hug V; Hortobagyi GN
    Cancer; 1987 Jun; 59(12):1992-9. PubMed ID: 3567861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
    Ghavamzadeh A
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S66-8. PubMed ID: 2347052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
    Aurer I; Nemet D; Mitrović Z; Dujmović D; Bašić-Kinda S; Radman I; Sertić D; Šantek F; Kralik M; Dotlić S; Mazić S; Labar B
    Ann Hematol; 2016 Jun; 95(7):1129-36. PubMed ID: 27103009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
    Loeffler TM; Weber FW; Hausamen TU
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.